BioDelivery Sciences International Inc
BioDelivery Sciences International — Investor Presentation (April 2009)
36 slides from BioDelivery Sciences International's investor presentation, Apr 3, 2009
Slide 1: Future Leaders in the Biotech Industry
All rights reserved Future Leaders in the Biotech Industry April 2, 2009 Dr. Mark A. Sirgo President & Chief Executive Officer NASDAQ: BDSI Exhibit 99.1
Slide 2: Notice Regarding Forward Looking Statements
Notice Regarding Forward Looking Statements Certain statements contained in this presentation or in other documents of BioDelivery Sciences International, Inc. (the “ Company ” ), along with certain statements that may be made by management of the Company orally in presenting this material, may cont
Slide 3: Corporate Highlights
Corporate Highlights SPECIALTY PHARMACEUTICAL COMPANY – Leverage novel proprietary patent-protected drug delivery technologies to rapidly advance the commercialization of new applications of proven therapeutics to address unmet market needs HIGH ROI DRUG DEVELOPMENT PLATFORM – Utilize the 505 (b)(2)
Slide 4: Key Value Driver: 1H 2009 Approval of ONSOLIS
Key Value Driver: 1H 2009 Approval of ONSOLIS™ Anticipated For Breakthrough Cancer Pain August 28, 2008: received a Complete Response Letter ONSOLIS™ Complete Response Content: – Conversion of risk minimization action plan (“RiskMAP”) to a risk evaluation mitigation strategy (“REMS”) – No other defi
Slide 5: Transmucosal Fentanyl Drug Delivery Technologies Competitive Landscape
Transmucosal Fentanyl Drug Delivery Technologies Competitive Landscape
Slide 6: Transmucosal Fentanyl Delivery Systems
Transmucosal Fentanyl Delivery Systems Actiq ® (1996) Fentora ® (2006) Formulation : Buccal tablet Administration : Place between cheek and gums above a molar. Allow to dissolve. After 30 minutes, if remnants still remain, swallow with a glass of water. Formulation : Oral transmucosal lozenge Admini
Slide 7: BEMA (BioErodible MucoAdhesive) Film Technology
BEMA ™ (BioErodible MucoAdhesive) Film Technology Bi-layered film technology Active drug in the muco- adhesive layer Backing layer facilitates unidirectional flow of drug Adheres to oral mucosa in < 5 seconds Dissolves within 15-30 minutes Designed to optimize delivery across the mucosa BEMA attribu
Slide 8: ONSOLIS - Profile and Attributes
ONSOLIS ™ - Profile and Attributes
Slide 9: Greater and More Rapid Absorption of Fentanyl Compared to Actiq
ONSOLIS™ 0.0 0.5 1.0 1.5 2.0 Time After Dose Administration (hours) 0.0 0.5 1.0 1.5 2.0 Greater and More Rapid Absorption of Fentanyl Compared to Actiq ® in this PK Study 40% Greater Absorption versus Actiq® The mean peak concentration was higher after ONSOLIS™ than Actiq® The median Tmax was shorte
Slide 10: ONSOLIS: Dose Proportionality Across Dose Range
1200 µg 600 µg 200 µg ONSOLIS ™: Dose Proportionality Across Dose Range Dose Proportionality Demonstrated Based on Linear Pharmacokinetics 0.0 0.5 1.0 1.5 2.0 2.5 Time (hr) ONSOLIS Plasma Fentanyl Concentrations Vasisht, et al. American Pain Society, Poster Presentation, May 2008.
Slide 11: ONSOLIS Attributes
Thin Film (simple placement) 2.0% * 0% * 200 – 1200 mcgs 3% * ONSOLIS ™ Attributes Convenient, Easy to use “Adheres – Delivers - Dissolves” Good Oral Tolerability - Incidence of drug-related application site AEs - Discontinued due to application site AEs Provides linear pharmacokinetics across full
Slide 12: ONSOLIS Market Opportunity
ONSOLIS ™ Market Opportunity
Slide 13: Significant Market Opportunity - Breakthrough Cancer Pain
1200 1000 1200 Cancer Patients CA + Pain BTP Significant Market Opportunity – Breakthrou g h Cancer Pain Current/Future Market Size: US cancer breakthrough pain market: Branded Drugs - sales estimated to grow from $400 mln ~$1.3 bln by 2017 Current Market Leaders : Fentora ™ : $182 million Actiq ® /
Slide 14: ONSOLIS Commercial Partner
ONSOLIS ™ Commercial Partner
Slide 15: ONSOLIS Global Commercialization Partner: MEDA AB
ONSOLIS ™ Global Commercialization Partner*: MEDA AB Intl specialty pharma based in Sweden 2,500 employees/1,650 com ops Sales: 2001 - 2007: $30M $1.3B Significant US presence via MedPointe (Carter Wallace) acquisition in 2007 Therapeutic expertise includes pain/inflammation (Soma ® , tramadol, NSAI
Slide 16: ONSOLIS Represents a Significant Financial Opportunity for BDSI
ONSOLIS ™ Represents a Significant Financial Opportunity for BDSI Financial Benefits to BDSI $30 million upon NDA approval and commercial launch* $30 million for achievement of specified sales milestones Significant double digit royalty Meda covers all future development costs for ONSOLIS including
Slide 17: Capital Efficient Business Model
<$25M Total Costs 3 Years Timeline to NDA Product Development Capital Efficient Business Model ONSOLIS ™ – Early and significant return on investment * Approval anticipated 1H09
Slide 18: Medium-Term Product Portfolio
Medium-Term Product Portfolio
Slide 19: BEMA Buprenorphine: Schedule III Narcotic
BEMA ™ Buprenorphine: Schedule III Narcotic BDSI’s Entry Into Broader Pain Market Market Need Rapidly escalating problem of opioid abuse and addiction in the US Short and long-term side effect issues with opioids Safety issues with COX-2 inhibitors and NSAIDS Development Goals Initial indication: Po
Slide 20: BEMA Buprenorphine Provides a Potential Alternative to CII Drugs
BEMA ™ Buprenorphine BEMA ™ Buprenorphine Provides a Potential Alternative to CII Drugs NSAID, COX-2 Weak opioid Severe Pain: Strong opioid Pain persisting or increasing Pain persisting or increasing Acute Pain: • Post operative • Musculoskeletal injuries • Acute low back pain Fentanyl Morphine OxyC
Slide 21: BEMA Buprenorphine Provides a Potential Alternative to CII Drugs
BEMA ™ Buprenorphine BEMA Buprenorphine Provides a Potential Alternative to CII Drugs Mild Pain: non-opioid Pain persisting or increasing Pain persisting or increasing OxyContin ® Duragesic ® Kadian/Avinza ® Chronic Pain Indications: •Back Pain •Osteoarthritis Tramadol Vicodin ® COX-2’s Naproxen Ibu
Slide 22: Moderate to Severe Pain Market Accounts for Over 50% of Units Sold
BEMA Buprenorphine will compete for this market segment >50% of units Moderate to Severe Pain Market Accounts for Over 50% of Units Sold Source: Wolters Kluwer Integrated Pharmaceutical Audits. Mild = APAP, salicylate, NSAIDs/COXII, Moderate to severe = hydrocodone, propoxyphene, codeine & combinati
Slide 23: BEMA Buprenorphine: Initial Formulation Pharmacokinetics
Suboxone 2 mg BEMA™ Buprenorphine Initial Formulation 2 mg BEMA ™ Buprenorphine: Initial Formulation Pharmacokinetics 0.2 0.4 0.6 0.8 1.2 1.4 1.6 Hours
Slide 24: BEMA Buprenorphine PK/PD Study
Suboxone 2 mg BEMA™ Buprenorphine Initial Formulation 2 mg BEMA™ Buprenorphine NEW Formulation 1 mg BEMA ™ Buprenorphine PK/PD Study – BEMA Buprenorphine Provides Rapid and High Blood Plasma Concentrations Hours 0.2 0.4 0.6 0.8 1.2 1.4 1.6
Slide 25: Bion viivery
Bion viivery A ANA TY
Slide 26: Slide 26
Slide 27: Slide 27
Slide 28: Slide 28
Slide 29: BEMA Buprenorphine: Market Positioning
Narcotic of choice in patients requiring acute or chronic pain treatment stepping up from NSAIDs or other non narcotic analgesics BEMA™ Buprenorphine: Market Positioning First Target: moderate to severe acute pain – Post-operative – Musculoskeletal Second Target: moderate to severe chronic pain – Lo
Slide 30: Bioral Drug Delivery Technology
Bioral ™ Drug Delivery Technology IV Oral Delivery
Slide 31: Bioral Amphotericin B: Potential First Oral Fungicidal
Bioral™ Amphotericin B: Potential First Oral Fungicidal Market Need Drug resistance to existing oral “fungistatic” agents leads to hospitalization and IV amphotericin B treatment No orally available agents Development Goals First oral fungicidal agent; Potential to prevent hospitalizations and/or fa
Slide 32: Phase 1 Study Results - Bioral Amphotericin B
Phase 1 Study Results - Bioral ™ Amphotericin B Hours 200 mg 400 mg 800 mg • Bioral ™ Amphotericin B was well-tolerated at single oral doses of & mg • Plasma concentrations of Amphotericin are comparable to prior results from animal studies * Abstract presented at the Focus on Fungal Infections Meet
Slide 33: Bioral Amphotericin B Development Timeline
Phase 3 Phase 2 Esophageal Candidiasis: Planned for 2011 Leishmaniasis 2010 (DND i , WRAIR)* Single dose pharmacokinetics completed 4Q 2008 Multi-dose pharmacokinetic study 2Q 2009 Phase 1 Bioral™ Amphotericin B Development Timeline* * Research and development partnership with Drugs for Neglected Di
Slide 34: Product Portfolio Summary
>$200 million * $500 million+* $400 Million* Pre-clinical Phase I Phase II Phase III NDA Filed Marketed Product ONSOLIS™ ( fentanyl buccal soluble film) Breakthrough Cancer Pain** BEMA™ Buprenorphine Moderate to Severe Pain Bioral ™ Amphotericin B Fungal Infections * peak sales potential, BDSI estim
Slide 35: 2009 Financial Highlights
2009 Financial Highlights ONSOLIS ™ NDA Approval & Launch Royalty on Sales of ONSOLIS ™ Cash Flow Positive From Operations $30.0 Million* Double-digit > $30 Million Potential Includes $3.0 million advance received January 2009
Slide 36: Investor Highlights: BDSI
Investor Highlights: BDSI* Near-Term Product Opportunity: ONSOLIS ™ (BEMA ™ Fentanyl) approval anticipated in 1H 2009, Strong Commercial Partner making ONSOLIS ™ #1 Global Priority Medium-Term Product Potential (BEMA ™ Buprenorphine, Bioral ™ Amphotericin B) = Revenue Growth Potential 2009 Key Finan
Biodelivery Sciences International — Investor Presentation (April 2009) on 6ix